Literature DB >> 10661662

AIDS incidence and survival in a hospital-based cohort of asymptomatic HIV seropositive patients in São Paulo, Brazil.

L A Fonseca1, A L Reingold, J R Casseb, L F Brigido, A J Duarte.   

Abstract

BACKGROUND: In spite of the high incidence of AIDS in Brazil, few studies have tried to evaluate the prognosis of asymptomatic HIV seropositive Brazilian patients.
METHODS: A hospital outpatient facility-based cohort of HIV seropositive asymptomatic subjects was followed to determine their probability of remaining AIDS-free at 2 and 4 years of follow-up, as well as the one-year estimated cumulative probability of survival for the AIDS incident cases. The cohort was made up of all asymptomatic HIV seropositive subjects referred to the Immunology Branch of a large university hospital in São Paulo, Brazil, between 1985 and June 1997.
RESULTS: The cumulative probability of remaining free from AIDS was 79% (+/- 3.7% SE) at 2 years, and 64.4% (+/- 5.1% SE) at 4 years after first known positive anti-HIV serology. Women had a marginally significant better probability of remaining AIDS-free after both 2 and 4 years of known seropositivity, as compared with men. There were no significant differences in the prognosis of the infection by age; the only single parameter associated with better prognosis was an initial CD4+ count > or =350/microl. The probability of survival one year after the diagnosis of AIDS was 78%, and the 50% estimated probability of survival was 19 months. Older patients (aged > or =35 years) had a better prognosis, as suggested by their longer survival estimates (P = 0.06).
CONCLUSIONS: The probability of survival with AIDS observed in this study was higher than in the few previously published estimates for Brazil. However, since the time frame was so wide, it may not be entirely comparable with earlier studies. Some likely explanations for this possibly better prognosis could include more efficient prophylaxis for opportunistic diseases, as well as an increase in the availability of anti-retroviral drugs. The 8% incidence of AIDS at 2 years observed in this study for those individuals whose initial CD4+ count was > or =350/ml was close to that found in a large international epidemiological study of seroconverters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10661662     DOI: 10.1093/ije/28.6.1156

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  5 in total

1.  Is the rate of CD4 cell decline changing over time in antiretroviral-naïve patients?

Authors:  Daniela Cardeal da Silva; Jorge Casseb; Ali Mirzazadeh; Liã B Arruda; George W Rutherford
Journal:  AIDS Patient Care STDS       Date:  2013-01-08       Impact factor: 5.078

2.  AIDS-defining illnesses among patients with HIV in Singapore, 1985 to 2001: results from the Singapore HIV Observational Cohort Study (SHOCS).

Authors:  Richard Bellamy; S Sangeetha; Nicholas I Paton
Journal:  BMC Infect Dis       Date:  2004-11-12       Impact factor: 3.090

3.  Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.

Authors:  Paula M Luz; Michael P Girouard; Beatriz Grinsztejn; Kenneth A Freedberg; Valdilea G Veloso; Elena Losina; Claudio J Struchiner; Rachel L MacLean; Robert A Parker; A David Paltiel; Rochelle P Walensky
Journal:  J Int AIDS Soc       Date:  2016-03-29       Impact factor: 5.396

Review 4.  Disparities in the Magnitude of Human Immunodeficiency Virus-related Opportunistic Infections Between High and Low/Middle-income Countries: Is Highly Active Antiretroviral Therapy Changing the Trend?

Authors:  M O Iroezindu
Journal:  Ann Med Health Sci Res       Date:  2016 Jan-Feb

Review 5.  Trends in overall opportunistic illnesses, Pneumocystis carinii pneumonia, cerebral toxoplasmosis and Mycobacterium avium complex incidence rates over the 30 years of the HIV epidemic: a systematic review.

Authors:  Lara Coelho; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn; Paula Mendes Luz
Journal:  Braz J Infect Dis       Date:  2013-11-23       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.